Press Releases

Announces Results of Two Posters on Iclaprim at ID Week 2015

By October 13, 2015No Comments

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced results of two iclaprim clinical studies that were presented at the Infectious Disease Week 2015 (ID Week) conference in San Diego, California on 9 October, 2015. Iclaprim is a novel antibiotic, targeting the bacterial dihydrofolate reductase enzyme, which is currently starting two Phase III clinical trials to treat acute bacterial skin and skin structure infections (ABSSSI).

Dr. David Huang, Chief Medical Officer at Motif, commented: “Data from these studies provides us with further confidence that iclaprim can perform well in the two Phase III trials in ABSSSI. Furthermore, the Phase II data in nosocomial pneumonia caused by Gram-positive bacteria, which are commonly identified as Staphylococcus aureus, including MRSA, provides good evidence that iclaprim may also be successful in our planned Phase III clinical trials to treat hospital-acquired and ventilator-associated bacterial pneumonia.”

The two posters:

“Cessation of Spread of Lesion and Absence of Fever at 72 hours in Complicated Skin and Skin Structure Infection (cSSSI): Reanalysis of the Combined ASSIST Phase III Study Comparing Iclaprim and Linezolid.”

This poster presented data on the reanalysis of two Phase III studies to treat cSSSI comparing iclaprim to linezolid, a standard of care treatment for SSSI, using endpoints similar to those based on the US Food and Drug Administration’s (FDA) recently changed guidelines for ABSSSI trials.

In the first Phase III study, patients who received iclaprim and linezolid had an early clinical response, defined as cessation of lesion spread and fever resolution at 72 hours of 73.9% and 71.4%, respectively: difference 2.5%; 95% confidence interval -5.6% to 10.6%.

In the second Phase III study, patients treated under the same treatment regimen had an early clinical response of 73.3% and 73.7%, respectively: difference -0.4%; 95% confidence interval -8.4% to 7.7%.

These data show that iclaprim achieved a high rate of early clinical response among patients with cSSSI.

“Randomized, Double-Blind, Multicenter Phase II Study to Evaluate Efficacy and Safety of Intravenous Iclaprim versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed Caused by Gram-positive Pathogens.”

This poster presented data on outcomes related to treatment with iclaprim compared to vancomycin, a standard of care treatment for Hospital-acquired bacterial pneumonia (HABP), ventilator-associated pneumonia (VAP) and healthcare-associated pneumonia (HCAP).

Patients who received a low dose of iclaprim, a high dose of iclaprim, and vancomycin had a clinical cure rate of 73.9%, 62.5%, and 52.2%, respectively.  Under the same treatment regime patients had a Day 28 mortality rate of 8.7%, 12.5%, and 21.7%, respectively.

These data show that iclaprim had high clinical cure rates and relatively low mortality rates among patients with HABP, VAP, and HCAP.

Enquiries

Motif Bio plc

Graham Lumsden, Chief Executive Officer
David Huang, Chief Medical Officer
info@motifbio.com

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Dan Bate
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners (Broker)

Patrick Claridge / David Hignell
John Howes / Mark Treharne (Broking)
+44 (0) 207 382 1100

MC Services AG (Trade PR)

Raimund Gabriel
Shaun Brown
+49 (0) 89 210 2280
+44 (0) 207 148 5998

Plumtree Capital Limited (Financial Advisor)

Stephen Austin
+44 (0) 207 183 2493

Yellow Jersey PR (Financial PR)

Charles Goodwin
Dominic Barretto
+44 (0) 7747 788 221

Notes to Editors

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.